Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.65) by 16.92 percent. This is a 14.89 percent decrease over losses of $(0.47) per share from the same period last year.
Camber Energy’s Viking Energy Files New Patent Application
Camber Energy, Inc.'s, (NYSE:CEI) ("Camber" or the "Company") majority-owned subsidiary, Viking Energy Group, Inc. ("Viking"), announced today that Viking's majority-owned
